Simvastatin Prevents and Reverses Depigmentation in a Mouse Model of Vitiligo
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Vitiligo is a common autoimmune disease of the skin that results in disfiguring white spots. There are no FDA-approved treatments, and current treatments are time-consuming, expensive, and have low efficacy. We sought to identify new treatments for vitiligo, and first considered repurposed medications because of the availability of safety data and expedited regulatory approval. We previously reported that the IFN-γ-induced chemokine CXCL10 is expressed in lesional skin from vitiligo patients, and that it is critical for the progression and maintenance of depigmentation in our mouse model of vitiligo. We hypothesized that targeting IFN-γ signaling might be an effective new treatment strategy. STAT1 activation is required for IFN-γ signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medication, inhibited STAT1 activation in vitro. Therefore, we hypothesized that simvastatin may be an effective treatment for vitiligo. We found that simvastatin both prevented and reversed depigmentation in our mouse model of vitiligo, and reduced the number of infiltrating autoreactive CD8+ T cells in the skin. Treatment of melanocyte-specific, CD8+ T cells in vitro decreased proliferation and IFN-γ production, suggesting additional effects of simvastatin directly on T cells. Based on these data, simvastatin may be a safe, targeted treatment option for patients with vitiligo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120 · cited 3×
“STAT1 is also phosphorylated by IL-12 (Schroder et al., 2004), a cytokine that induces IFN-g production, and certain STAT1 mutations in humans result in decreased IFN-g production after IL-12 stimulation (van de Veerdonk et al.”
BackgroundMeraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81288-x · Cited by 1,656 · cited 2×
“Mice with selective STAT1-deficiency have impaired IFN-induced signaling and target gene expression (Meraz et al., 1996), although some IFN-induced genes may be STAT1-independent (Ramana et al., 2001).”
BackgroundBickers (2006) · doi:10.1016/j.jaad.2006.05.048 · Cited by 741
A novel anti-inflammatory role for simvastatin in inflammatory arthritis.
Leung, B. P., Sattar, N., Crilly, A., Prach, M., McCarey, D. W., Payne, H., Madhok, R., Campbell, C., Gracie, J. A., Liew, F. Y., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1524 · Cited by 434
Cited by
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
Richmond, J. M., Strassner, J. P., Zapata, L., Garg, M., Riding, R. L., Refat, M. A., Fan, X., Azzolino, V., Tovar-Garza, A., Tsurushita, N., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7710 · Cited by 301
Self-citationAlopecia areata: a review of disease pathogenesis
Rajabi, F., Drake, L. A., Senna, M. M., & Rezaei, N. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16808 · Cited by 296
Vitiligo: A focus on pathogenesis and its therapeutic implications
Bergqvist, C., & Ezzedine, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15743 · Cited by 277
Minz, A. P., Mohapatra, D., Dutta, M., Sethi, M., Parida, D., Mohapatra, A. P., Mishra, S., Kar, S., Sasmal, P. K., & Senapati, S. (2023) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-023-03562-9 · Cited by 24
“However, earlier studies suggest a requirement of high dose statins use in rodents because of their rapid upregulation of HMG-CoA reductase upon treatment [69, 70].”
Background
Metadata
- Authors
- Agarwal, P., Rashighi, M., Essien, K. I., Richmond, J. M., Randall, L., Pazoki-Toroudi, H., Hunter, C. A., & Harris, J. E.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 135
- Issue
- 4
- Pages
- 1080-1088
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2139070921
- Cited by
- 110
- References
- 4
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.